Real-world outcomes of sequencing elotuzumab (elo)-based regimens following daratumumab (dara) in patients with relapsed/refractory multiple myeloma: results from the Connect (R) MM Registry
Clinical Lymphoma Myeloma and Leukemia（2022）
关键词
relapsed/refractory multiple myeloma,multiple myeloma,elotuzumab,daratumumab,real-world
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要